Actuate Therapeutics (ACTU) risk factors

Item 1A of every Actuate Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open ACTU in Gloom →

Actuate Therapeutics' chart, financials and news, free in your browser.Open ACTU in Gloom →

FY2025 10-K risk factors
45 risks3 new41 dropped19 reworded
Actuate Therapeutics discloses cash runway only extending to July 2026 for its sole drug candidate, elraglusib. Reliance on a single drug substance manufacturer in China creates geopolitical supply chain risks.
Filed Mar 26, 2026
FY2024 10-K risk factors
83 risks
Actuate Therapeutics has a limited operating history with no commercial products and faces going concern risks with only $8.6 million in cash.
Filed Mar 13, 2025